Efficacy and safety of midazolam and vesparax in treatment of sleep disorders.
In a double-blind parallel study in which a placebo phase preceded and followed the double-blind verum phase, midazolam 15 mg and Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine) were administered to 30 female patients aged 20-76 years, suffering from insomnia secondary to neuromuscular disease. Both products were shown to be efficient hypnotics maintaining a constant level of effect. Midazolam proved to be better tolerated and, in contrast to Vesparax, did not cause hangover, nor did rebound phenomena ensue after its withdrawal.
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001463:Barbiturates / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006919:Hydroxyzine / Q000009:adverse effects / Q000627:therapeutic use*; D008874:Midazolam; D008875:Middle Aged; D012631:Secobarbital / Q000009:adverse effects / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D001463:Barbiturates; D004338:Drug Combinations; C013332:brallobarbital, hydroxyzine, secobarbital drug combination; D001569:Benzodiazepines; D012631:Secobarbital; D006919:Hydroxyzine; D008874:Midazolam